CB1 Capital Management predicts Cannabis could disrupt the healthcare industry in a big way. The firm's Founding Partner and Chief Investment Officer Todd Harrison explains why he thinks medical marijuana will migrate from state dispensaries, to become medicine prescribed by doctors through insurance in the next decade.
Harrison says the only way the U.S. government would get their hands on the money in this market opportunity is through the FDA. "That's where we think it goes, follow the money," says Harrison.
"This is not so much a trade about commerce, as it is a trade about healthcare," said Harrison. "We think that this is going to migrate towards medicine." One of CB1 Capital Management's holdings GW Pharmaceuticals is up 30 percent over the past three months. Harrison expects this company to publish research showing the efficacy of cannabis treatment this summer.
Hear from Gabino & Stephen Roche on Saphyre’s institutional AI platform that centralizes pre‑ and post‑trade data, redefining settlement speed and accuracy.
Explore how Guident’s cutting-edge software is shaping the future of autonomous vehicles with CEO Harald Braun. Safety, control & AI at the wheel of innovation.
Wondercraft co-founder Oskar Serrander discusses the booming AI audio industry, deepfake risks, and the growing market for synthetic, AI-generated content.
Comerica’s Chief Economist Bill Adams unpacks U.S. retail sales, job growth, and the resurgence of market volatility—and what it all signals for the economy.
Saar Yoskovitz, CEO of Augury, shares how the company delivers AI infrastructure that Fortune 500s rely on to boost efficiency, reliability, and scale.
